Good MorningEquity markets after a round of stronger-than-expected economic data. The Q4 GDP came in at 2.9% and a tenth hotter than expected on strong labor conditions and consumer health. The takeaway is that the underlying strength in the economy is supporting activity among S&P 500 companies but also inflation. The recent downtick in inflation is good news but may not be sustainable given the economic strength. In this light, the market's expectation for only a 25 basis rate hike at the next FOMC meeting may be misplaced.
The entire outlook could change today upon the release of the December PCE price index. The index is expected to confirm the downtick in consumer-level inflation but the data will most likely be mixed. While YOY comparisons will cool, inflation is expected to have accelerated on a month-to-month basis and may come in hot. In this scenario, the odds of a 25 basis point hike will crater and the S&P 500 could fall with it. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Technology | |
Switzerland-based chipmaker STMicroelectronics N.V. (NYSE: STM) gapped 7.75% on January 26 after significantly topping analysts’ views for fourth-quarter earnings.
The company earned $1.32 per share on revenue of $4.42 billion, topping analyst views of $1.13. Wall Street had expected reven... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Energy | |
The energy boom is back, and Houston-based oil-and-gas industry supplier NOV Inc. (NYSE: NOV) is capitalizing on the renewed uptrend.
The stock advanced more than 6% for the week, as of January 26. The broader large-cap energy sector, as tracked by the Energy Select Sector SPDR Fund (NYSEARCE: XL... Read the Full Story |
|
Technology | |
E-commerce platform Shopify Inc. (NYSE: SHOP) cleared a cup-with-handle base on January 24, with a buy point above $45.16.
The surge followed a Shopify blog post after the market close on January 23, announcing price increases.
The stock is up 36.36% in January, with a one-week gain of 20.83%.... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Markets | |
Have you ever wondered what the future of e-commerce will look like?
With its e-commerce projection through 2026, the consulting firm offers us a glimpse into the future.
This report answers concerns regarding potential changes in the online market, potential effects of technology on the sector... Read the Full Story |
|
Energy | |
Before the company’s earnings report on January 27, Chevron Corporation (NYSE: CVX) announced a $75 billion share buyback program. This triples the company’s budget for share buybacks. Not surprisingly, CVX stock is up nearly 3% in morning trading.
The company is also increasing its... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
Levi Strauss & Co. (NYSE: LEVI) received several downgrades and price target reductions ahead of the Q4 earnings report that, frankly, failed to account for the company’s brand strength, market position, DTC channels and the underlying strength in the consumer that continues to underpin ... Read the Full Story |
|
Consumer Staples | |
Will the real U.S. equity market please stand up?
Thus far, 2023 has brought a mixed bag of relief rallies and disappointing corporate updates. As a result, the market has been in 'risk-on' mode, with investors shunning bleak outlooks by buying pullbacks.
There's much debate about the current ra... Read the Full Story |
|
Consumer Discretionary | |
Mullen Automotive's (NASDAQ: MULN) price action is heating up again, and the charts look as good as ever. The caveat is that short-selling and bearish activity is just as hot as ever and will likely keep the action volatile, if nothing else. The latest news from the company is the results of the s... Read the Full Story |
|
Healthcare | |
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $6 billion sale of LHC Group Inc. (Nasdaq: LHCG) to UnitedHealth (NYSE: UNH) and the $8 billion... Read the Full Story |
|
Technology | |
Apple Inc (NASDAQ: APPL) wants to increase its manufacturing presence in India and sidestep its reliance on Chinese manufacturing capabilities.
The company intends to create 25% of all of its iPhones on Indian soil, which is part of its broader pivot of having 40% of its devices made outside Chin... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. | | View Today's Stock Pick |
|
